Results from two phase II studies were highly concordant for poziotinib, indicating modest antitumor activity in previously treated patients with NSCLC and HER2 exon 20 insertion mutations, with an ORR of about 27% [40,41]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.